HighVista Strategies LLC Has $1.05 Million Position in CG Oncology, Inc. $CGON

HighVista Strategies LLC boosted its stake in shares of CG Oncology, Inc. (NASDAQ:CGON) by 152.1% in the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 26,040 shares of the company’s stock after purchasing an additional 15,712 shares during the quarter. HighVista Strategies LLC’s holdings in CG Oncology were worth $1,049,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in CGON. PNC Financial Services Group Inc. raised its position in shares of CG Oncology by 15.2% in the second quarter. PNC Financial Services Group Inc. now owns 3,279 shares of the company’s stock valued at $85,000 after purchasing an additional 433 shares during the period. CWM LLC boosted its holdings in shares of CG Oncology by 10.9% during the 3rd quarter. CWM LLC now owns 6,865 shares of the company’s stock worth $277,000 after buying an additional 672 shares during the period. Strengthening Families & Communities LLC bought a new stake in shares of CG Oncology during the 3rd quarter worth $40,000. Swiss National Bank grew its stake in CG Oncology by 1.5% in the 3rd quarter. Swiss National Bank now owns 81,300 shares of the company’s stock valued at $3,275,000 after buying an additional 1,200 shares during the last quarter. Finally, Police & Firemen s Retirement System of New Jersey raised its holdings in CG Oncology by 10.6% in the 2nd quarter. Police & Firemen s Retirement System of New Jersey now owns 12,879 shares of the company’s stock worth $335,000 after acquiring an additional 1,232 shares during the period. Institutional investors and hedge funds own 26.56% of the company’s stock.

Insider Activity at CG Oncology

In other news, Director James Mulay sold 11,145 shares of CG Oncology stock in a transaction dated Friday, January 9th. The shares were sold at an average price of $52.47, for a total transaction of $584,778.15. The sale was disclosed in a document filed with the SEC, which is available through the SEC website.

CG Oncology Trading Up 2.5%

Shares of NASDAQ CGON opened at $65.90 on Tuesday. The firm has a market capitalization of $5.56 billion, a price-to-earnings ratio of -31.84 and a beta of 1.17. CG Oncology, Inc. has a one year low of $14.80 and a one year high of $66.81. The business has a fifty day simple moving average of $55.18 and a 200 day simple moving average of $45.11.

CG Oncology (NASDAQ:CGON) last posted its quarterly earnings results on Friday, February 27th. The company reported ($0.51) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.61) by $0.10. The business had revenue of $2.32 million for the quarter. On average, research analysts anticipate that CG Oncology, Inc. will post -1.31 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of research firms have weighed in on CGON. HC Wainwright boosted their target price on shares of CG Oncology from $75.00 to $80.00 and gave the stock a “buy” rating in a research report on Friday, February 27th. Wedbush assumed coverage on CG Oncology in a research report on Thursday, December 11th. They issued an “outperform” rating and a $70.00 price target on the stock. The Goldman Sachs Group reissued a “buy” rating and set a $82.00 price objective on shares of CG Oncology in a research report on Monday, January 12th. Weiss Ratings restated a “sell (d-)” rating on shares of CG Oncology in a research note on Wednesday, January 21st. Finally, Royal Bank Of Canada raised their target price on CG Oncology from $61.00 to $73.00 and gave the company an “outperform” rating in a report on Wednesday, January 21st. Eleven equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $69.00.

CG Oncology Profile

CG Oncology, Inc (NASDAQ: CGON) is a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibody-based immunotherapies for the treatment of solid tumor cancers. The company leverages a platform-driven approach to identify and optimize antibody candidates that engage key immune checkpoints and co-stimulatory pathways within the tumor microenvironment. Its pipeline encompasses multiple preclinical programs alongside early-phase clinical trials designed to assess safety, dosing and preliminary anti-tumor activity.

Headquartered in South San Francisco, California, CG Oncology conducts clinical research primarily in the United States, collaborating with leading academic medical centers and contract research organizations to advance its lead candidates.